Preclinical efficacy of azacitidine and venetoclax for infant kmt2a-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

HIGHLIGHTS

• who: Laurence C. Cheung from the (UNIVERSITY) have published the research work: Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy, in the Journal: (JOURNAL) of 15/Nov/2022
• what: The aims of this study were to (i) investigate the benefit of hypomethylating agents for infants with KMT2Arearranged ALL, (ii) elucidate the effect of these drugs on the methylome, transcriptome and identify their target protein binding landscape and_(iii) determine the benefit of adding the selective BCL-2 inhibitor, venetoclax, to treatment for infants with KMT2A . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.